Application of targeted mass spectrometry in bottom-up proteomics for systems biology research

Abstract

The enormous diversity of proteoforms produces tremendous complexity within cellular proteomes, facilitates intricate networks of molecular interactions, and constitutes a formidable analytical challenge for biomedical researchers. Currently, quantitative whole-proteome profiling often relies on non-targeted liquid chromatography-mass spectrometry (LC-MS), which samples proteoforms broadly, but can suffer from lower accuracy, sensitivity, and reproducibility compared with targeted LC-MS. Recent advances in bottom-up proteomics using targeted LC-MS have enabled previously unachievable identification and quantification of target proteins and posttranslational modifications within complex samples. Consequently, targeted LC-MS is rapidly advancing biomedical research, especially systems biology research in diverse areas that include proteogenomics, interactomics, kinomics, and biological pathway modeling. With the recent development of targeted LC-MS assays for nearly the entire human proteome, targeted LC-MS is positioned to enable quantitative proteomic profiling of unprecedented quality and accessibility to support fundamental and clinical research. Here we review recent applications of bottom-up proteomics using targeted LC-MS for systems biology research. SIGNIFICANCE: Advances in targeted proteomics are rapidly advancing systems biology research. Recent applications include systems-level investigations focused on posttranslational modifications (such as phosphoproteomics), protein conformation, protein-protein interaction, kinomics, proteogenomics, and metabolic and signaling pathways. Notably, absolute quantification of metabolic and signaling pathway proteins has enabled accurate pathway modeling and engineering. Integration of targeted proteomics with other technologies, such as RNA-seq, has facilitated diverse research such as the identification of hundreds of "missing" human proteins (genes and transcripts that appear to encode proteins but direct experimental evidence was lacking).

Identification of significant protein markers by mass spectrometry after co‐treatment of cells with different drugs: An in vitro survey platform

“…Despite rapid development in MS‐based proteomics over the last 20 years, to date the US Food and Drug Administration (FDA) has approved only around 109 unique protein markers including over 20 protein‐based cancer biomarkers . Proteomics using mass spectrometry has developed into a powerful and highly versatile technology that is enabling rapid advances in diverse areas of biomedical research, clinical diagnostics, and biotechnology . Huh‐7 cells have been used to investigate the liver toxicity of drugs, the molecular mechanisms of hepatic gene regulation, and drug efficacy; hence, we selected Huh‐7 cells as a study model.…”

Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies

“…Here we focus on untargeted approaches and how they can be used to help understand cellular biology. More information on targeted approaches can be found in other reviews [21,22].…”

The Discovery of Clinically Applicable Biomarkers for Bipolar Disorder: A Review of Candidate and Proteomic Approaches

“…Mass spectrometry with liquid chromatography -mass spectrometry (LC-MS-MS) and matrix-assisted laser desorption/ionization -time of flight (MALDI-TOF/TOF) are extensively applied tools and are principal amongst contemporary protein analysis techniques. 49 1) A systematic review of the literature: In order to gauge the potential of proteomics for biomarker discovery, in February 2020, the PubMed electronic data base was queried by a variety of search terms including, "proteomics and bipolar disorder", "proteomics and mood disorders", "major depressive disorder and proteomic biomarkers", and "schizophrenia and proteomic biomarkers". A large number of articles, totaling more than 500, were recovered.…”